Astrana Health (NASDAQ:ASTH) Price Target Raised to $65.00

Astrana Health (NASDAQ:ASTH) had its price target lifted by BTIG Research from $50.00 to $65.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price indicates a potential upside of 36.44% from the stock’s previous close.

A number of other brokerages have also recently commented on ASTH. Barclays upgraded Astrana Health from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $37.00 to $50.00 in a report on Tuesday, May 26th. Needham & Company LLC raised their target price on shares of Astrana Health from $30.00 to $41.00 and gave the stock a “buy” rating in a report on Friday, May 8th. TD Cowen lifted their price target on shares of Astrana Health from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Robert W. Baird set a $45.00 price target on shares of Astrana Health in a report on Friday, May 8th. Finally, Weiss Ratings raised shares of Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 1st. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.14.

Astrana Health Price Performance

NASDAQ:ASTH opened at $47.64 on Tuesday. The company has a market capitalization of $2.65 billion, a P/E ratio of 78.10 and a beta of 0.89. The business’s 50-day moving average is $40.59 and its 200 day moving average is $30.69. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 1.20. Astrana Health has a 12 month low of $18.08 and a 12 month high of $51.60.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.45. Astrana Health had a return on equity of 9.22% and a net margin of 0.86%.The business had revenue of $965.10 million for the quarter, compared to analysts’ expectations of $949.21 million. During the same period in the prior year, the firm earned $0.42 EPS. The company’s revenue for the quarter was up 55.6% on a year-over-year basis. On average, equities research analysts forecast that Astrana Health will post 1.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astrana Health

A number of hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC increased its position in shares of Astrana Health by 57.9% during the fourth quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock worth $26,000 after acquiring an additional 388 shares during the period. GAMMA Investing LLC increased its holdings in Astrana Health by 144.7% during the 4th quarter. GAMMA Investing LLC now owns 1,473 shares of the company’s stock worth $37,000 after purchasing an additional 871 shares during the period. Swiss National Bank increased its holdings in Astrana Health by 1.2% during the 3rd quarter. Swiss National Bank now owns 86,944 shares of the company’s stock worth $2,465,000 after purchasing an additional 1,000 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Astrana Health by 5.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock valued at $799,000 after purchasing an additional 1,263 shares in the last quarter. Finally, Deutsche Bank AG raised its position in Astrana Health by 3.9% during the 4th quarter. Deutsche Bank AG now owns 41,265 shares of the company’s stock valued at $1,024,000 after purchasing an additional 1,550 shares in the last quarter. 52.77% of the stock is currently owned by institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.